Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10341120 | 0.88 | NPC1 (0.63) | SMN1; SMN2L3MBTL1ALDH1A1POLBTSHR | |
| SCHEMBL22691765 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2L3MBTL1ALDH1A1POLBTSHR | |
| SCHEMBL28860065 | 0.84 | NPC1 (0.54) | SMN1; SMN2L3MBTL1ALDH1A1POLBTSHR | |
| SCHEMBL10744349 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1ALDH1A1POLBTSHR | |
| SCHEMBL9075962 | 0.83 | MAPT (0.47) | SMN1; SMN2L3MBTL1ALDH1A1POLBTSHR | |
| SCHEMBL27683910 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2L3MBTL1ALDH1A1POLBTSHR | |
| SCHEMBL20809605 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2L3MBTL1ALDH1A1POLBTSHR | |
| SCHEMBL7658914 | 0.82 | POLB (0.57) | SMN1; SMN2L3MBTL1ALDH1A1POLBTSHR | |
| SCHEMBL8684761 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1ALDH1A1POLBTSHR | |
| SCHEMBL2590383 | 0.81 | NPC1 (0.56) | SMN1; SMN2L3MBTL1ALDH1A1POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292576-B | Triphenylamine-based photo-thermal small molecule and preparation method and application thereof | 山西大学 | 2023-05-30 | — | — | CN | claimed |
| CN-113292576-A | Triphenylamine-based photo-thermal small molecule and preparation method and application thereof | 山西大学 | 2021-08-24 | — | — | CN | claimed |
| CN-113292576-B | Triphenylamine-based photo-thermal small molecule and preparation method and application thereof | 山西大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-113292576-A | Triphenylamine-based photo-thermal small molecule and preparation method and application thereof | 山西大学 | 2021-08-24 | — | — | CN | disclosed |
| CN-103387583-B | Diaryl simultaneously [a, g] quinolizine class compound, its preparation method, pharmaceutical composition and its application | 中国科学院上海药物研究所 | 2018-04-13 | — | — | CN | disclosed |
| CN-103387583-A | Diaryl [a, g] quinolizidine compound, preparation method thereof, pharmaceutical composition, and uses thereof | SHANGHAI INST MATERIA MEDICA | 2013-11-13 | — | — | CN | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| CN-1938273-B | Tetrahydrocarbazoles and derivatives | HOFFMAN-LA ROCHE LTD. (CH) | 2011-12-14 | — | — | CN | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-10-21 | — | — | US | disclosed |
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-10-21 | — | — | US | disclosed |
| EP-2220044-A1 | P38 MAP KINASE INHIBITORS | Chroma Therapeutics Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| CN-101490003-A | New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | CN | disclosed |
| WO-2009060160-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009060160-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-14 | — | — | WO | disclosed |
| CN-1938273-A | Tetrahydrocarbazoles and derivatives | HOFFMANN LA ROCHE (CH) | 2007-03-28 | — | — | CN | disclosed |
| CN-1205198-C | Cyclic ketone derivative and pharmaceutical use thereof | TORAY INDUSTRIES (JP) | 2005-06-08 | — | — | CN | disclosed |
| CN-1242770-A | Cyclic ketone derivative and pharmaceutical use thereof | TORAY INDUSTRIES (JP) | 2000-01-26 | — | — | CN | disclosed |
| US-5633379-A | N-METHYLASPARTIC ACID ANTAGONIST | CIBA-GEIGY CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| EP-0685466-A1 | 3-Heteroaliphatyle-and 3-hetero-(aryle)-aliphatyle-2(1H)-quinolone derivatives | CIBA-GEIGY AG (CH) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK12 | SMN1; SMN2 3961/4885L3MBTL1 2188/4885ALDH1A1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.